Chargement en cours...
BCL-2 inhibition in AML: an unexpected bonus?
B-cell lymphoma 2 (BCL-2) was discovered at the breakpoint of the t(14;18) in follicular lymphoma >30 years ago. Although inhibition of BCL-2 first proved valuable in lymphoid malignancies, clinical progress in myeloid malignancies lagged. Here, we summarize the basic biology and preclinical resu...
Enregistré dans:
| Publié dans: | Blood |
|---|---|
| Auteurs principaux: | , |
| Format: | Artigo |
| Langue: | Inglês |
| Publié: |
American Society of Hematology
2018
|
| Sujets: | |
| Accès en ligne: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6235069/ https://ncbi.nlm.nih.gov/pubmed/30037885 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1182/blood-2018-03-828269 |
| Tags: |
Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!
|